Revelation Biosciences Q1 2025 10-Q Filed
Ticker: REVBW · Form: 10-Q · Filed: May 8, 2025 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, equity-warrants, stock-options, financial-reporting
Related Tickers: REVB
TL;DR
REVB Q1 10-Q is in! Lots of warrants and stock options detailed. Check dilution.
AI Summary
Revelation Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details various financial instruments including Class F Common Stock Warrants issued on December 3, 2024, and Class D Common Stock Warrants from January 1 to March 31, 2025. The company also reported on its Incentive Stock Options and Restricted Stock under the Two Thousand And Twenty One Equity Incentive Plan as of March 31, 2025.
Why It Matters
This filing provides investors with an update on Revelation Biosciences' financial position and equity instruments, crucial for understanding potential dilution and future share structure.
Risk Assessment
Risk Level: medium — The company's focus on equity instruments like warrants and stock options suggests potential future dilution and financial complexities.
Key Numbers
- 20250331 — Reporting Period End (Quarterly financial update)
- 20250508 — Filing Date (Date the report was submitted)
Key Players & Entities
- REVELATION BIOSCIENCES, INC. (company) — Filer
- Petra Acquisition Inc. (company) — Former Company Name
- 20250331 (date) — Reporting Period End Date
- 20250508 (date) — Filing Date
- ClassFCommonStockWarrantsMember (financial_instrument) — Equity Instrument
- ClassDCommonStockWarrantsMember (financial_instrument) — Equity Instrument
- TwoThousandAndTwentyOneEquityIncentivePlanMember (plan) — Equity Incentive Plan
FAQ
What is the total number of outstanding warrants as of March 31, 2025?
The filing does not explicitly state the total number of outstanding warrants as of March 31, 2025, but details various classes of warrants issued and their terms.
What is the exercise price for the Class F Common Stock Warrants?
The filing mentions the issuance of Class F Common Stock Warrants on December 3, 2024, but does not specify the exercise price in the provided snippet.
How many restricted stock units were granted under the Two Thousand And Twenty One Equity Incentive Plan?
The filing indicates the presence of Rollover Restricted Stock Units as of March 31, 2025, and March 31, 2024, but does not provide the exact number granted.
What was the company's cash position at the end of the reporting period?
The provided snippet of the 10-Q filing does not contain information on the company's cash position.
Are there any significant changes in the company's debt structure reported in this filing?
The provided snippet of the 10-Q filing does not contain information regarding changes in the company's debt structure.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding REVELATION BIOSCIENCES, INC. (REVBW).